News + Filings Transactions Holdings
All 13F 13D/G Other
|
Clarus Lifesciences II, L.P.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/12/2019 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 0.3% stake in NanoString Technologies, Inc. |
03/22/2019 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 6.1% stake in NanoString Technologies, Inc. |
03/22/2019 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on NanoString Technologies Inc
Txns:
| Sold 2,000,000 shares
@ $21.62, valued at
$43.2M
|
|
02/14/2019 |
SC 13G/A
| Clarus Lifesciences II, L.P. reports a 4.2% stake in Restoration Robotics, Inc. |
09/19/2018 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on NanoString Technologies Inc
Txns:
| Sold 85,823 shares
@ $15.99, valued at
$1.4M
Exercised (in-or-at-the-money) 162,408 warrants
@ $8.448, valued at
$1.4M
|
|
07/25/2018 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 14% stake in NanoString Technologies, Inc. |
04/04/2018 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 7% stake in Catabasis Pharmaceuticals, Inc. |
02/12/2018 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2018 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 12% stake in Catabasis Pharmaceuticals, Inc. |
01/03/2018 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on NanoString Technologies Inc
Txns:
| Granted 10,168 options to buy
@ $7.47, valued at
$76k
|
|
10/17/2017 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on Restoration Robotics Inc
Txns:
| Converted 3,389,105 shares
@ $0 Converted 180,881 shares
@ $7, valued at
$1.3M
Converted 3,389,105 preferred shares
@ $0 Converted convertible notes
@ $7, valued at
$0 |
|
10/13/2017 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on Restoration Robotics Inc
Txns:
| Acquired convertible notes
@ $7, valued at
$0 |
|
10/11/2017 |
3
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 3 on Restoration Robotics Inc |
06/07/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/13/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
01/04/2017 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on NanoString Technologies Inc
Txns:
| Granted 8,611 options to buy
@ $22.3, valued at
$192k
|
|
10/04/2016 |
SC 13D/A
| CATABASIS PHARMACEUTICALS INC reports a 15.4% stake in Catabasis Pharmaceuticals, Inc. |
03/16/2016 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 0% stake in TetraLogic Pharmaceuticals Corporation |
02/10/2016 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on TETRALOGIC PHARMACEUTICALS CORP |
02/05/2016 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on TETRALOGIC PHARMACEUTICALS CORP |
02/05/2016 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 16% stake in TetraLogic Pharmaceuticals Corporation |
11/04/2013 |
SC 13D
| Clarus Lifesciences II, L.P. reports a 16.5% stake in Aerie Pharmaceuticals, Inc. |
10/28/2013 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on AERIE PHARMACEUTICALS INC |
10/25/2013 |
3
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 3 on AERIE PHARMACEUTICALS INC |
10/02/2013 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on Ophthotech Corp. |
06/25/2013 |
3
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 3 on NanoString Technologies Inc |
06/06/2012 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on ACHILLION PHARMACEUTICALS INC
Txns:
| Disposed of 10,942,468 shares
@ $0 |
|
06/04/2012 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/25/2010 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
08/20/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/13/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/08/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/08/2010 |
SC 13D/A
| Clarus Lifesciences II, L.P. reports a 20.1% stake in Achillion Pharmaceuticals, Inc. |
12/29/2009 |
4
| Clarus Lifesciences II, L.P. (10% Owner) has filed a Form 4 on ACHILLION PHARMACEUTICALS INC
Txns:
| Sold 3,600 shares
@ $3.5264, valued at
$12.7k
|
|
|
|
|